8-K Announcements
6Material company update
Mar 23, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 20, 2026·SEC
Exact Sciences Corporation(EXAS)Earnings, Financials & Key Ratios
EXAS•NASDAQ
Price updated Apr 24, 2026
AboutExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Show more
- Revenue$3.25B+17.7%
- EBITDA-$206M+75.3%
- Net Income-$208M+79.8%
- EPS (Diluted)-1.10+80.3%
- Gross Margin69.69%+0.2%
- EBITDA Margin-6.35%+79.0%
- Operating Margin-6.35%+83.3%
- Net Margin-6.4%+82.8%
- ROE-8.66%+76.7%
EXAS Key Insights
Exact Sciences Corporation (EXAS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓Strong 5Y sales CAGR of 16.8%
- ✓Trading near 52-week high
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EXAS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EXAS Price & Volume
Exact Sciences Corporation (EXAS) stock price & volume — 10-year historical chart
Loading chart...
EXAS Growth Metrics
Exact Sciences Corporation (EXAS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years55.44%
5 Years16.84%
3 Years15.92%
TTM17.69%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM79.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM80.3%
Return on Capital
10 Years-17.61%
5 Years-10.54%
3 Years-8.81%
Last Year-3.96%
EXAS Recent Earnings
Exact Sciences Corporation (EXAS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 11/12 qtrs (92%)
Q1 2026Latest
Feb 13, 2026Metric
Actual
Est
EPS
$0.45-316.9%
$0.11
Rev
$878M+2.0%
$861M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.24+492.0%
$0.06
Rev
$851M+5.0%
$811M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.22+1200.0%
$0.02
Rev
$811M+0.1%
$810M
Q2 2025
May 1, 2025Metric
Actual
Est
EPS
$0.21+43.2%
$0.37
Rev
$707M+2.6%
$689M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 13, 2026 | $0.45vs $0.11-316.9% | $878Mvs $861M+2.0% |
| Q4 2025 | Nov 3, 2025 | $0.24vs $0.06+492.0% | $851Mvs $811M+5.0% |
| Q3 2025 | Aug 6, 2025 | $0.22vs $0.02+1200.0% | $811Mvs $810M+0.1% |
| Q2 2025 | May 1, 2025 | $0.21vs $0.37+43.2% | $707Mvs $689M+2.6% |
Based on last 12 quarters of dataView full earnings history →
EXAS Peer Comparison
Exact Sciences Corporation (EXAS) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GH | 17.47B | 131.78 | -39.69 | 32.88% | -40.1% | |||
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 LH | 21.05B | 255.82 | 24.46 | 7.25% | 6.66% | 10.89% | 0.83 | |
 DGX | 21.58B | 195.00 | 22.29 | 11.78% | 9.08% | 13.8% | 0.95 | |
 NEOG | 2.03B | 9.31 | -1.85 | -3.2% | -68.47% | -28.64% | 0.44 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare EXAS vs Peers
Exact Sciences Corporation (EXAS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EXAS Income Statement
Exact Sciences Corporation (EXAS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 265.99M | 454.46M | 876.29M | 1.49B | 1.77B | 2.08B | 2.5B | 2.76B | 3.25B |
Revenue Growth % | 167.66% | 70.86% | 92.82% | 70.19% | 18.49% | 17.95% | 19.93% | 10.37% | 17.69% |
Cost of Goods Sold | 79.2M | 117.98M | 216.72M | 354.3M | 458.76M | 661.36M | 737.6M | 840.2M | 984.24M |
COGS % of Revenue | 29.77% | 25.96% | 24.73% | 23.76% | 25.96% | 31.73% | 29.51% | 30.45% | 30.31% |
Gross Profit | 186.79M▲ 0% | 336.48M▲ 80.1% | 659.58M▲ 96.0% | 1.14B▲ 72.4% | 1.31B▲ 15.1% | 1.42B▲ 8.8% | 1.76B▲ 23.8% | 1.92B▲ 8.9% | 2.26B▲ 17.9% |
Gross Margin % | 70.23% | 74.04% | 75.27% | 76.24% | 74.04% | 68.27% | 70.49% | 69.55% | 69.69% |
Gross Profit Growth % | 244.76% | 80.14% | 96.02% | 72.4% | 15.06% | 8.76% | 23.84% | 8.88% | 17.93% |
Operating Expenses | 305.1M | 495.95M | 893.36M | 1.9B | 2.16B | 2.02B | 1.98B | 2.97B | 2.46B |
OpEx % of Revenue | 114.71% | 109.13% | 101.95% | 127.72% | 122.46% | 96.74% | 79.09% | 107.56% | 75.82% |
Selling, General & Admin | 262.96M | 427.74M | 737.63M | 1.07B | 1.66B | 1.59B | 1.62B | 1.67B | 1.94B |
SG&A % of Revenue | 98.86% | 94.12% | 84.18% | 71.83% | 94.12% | 76.43% | 64.82% | 60.46% | 59.71% |
Research & Development | 42.14M | 68.21M | 139.69M | 554.05M | 385.65M | 394.19M | 426.93M | 431.21M | 523M |
R&D % of Revenue | 15.84% | 15.01% | 15.94% | 37.15% | 21.82% | 18.91% | 17.08% | 15.63% | 16.11% |
Other Operating Expenses | 0 | 0 | 16.04M | 279.42M | 115.21M | 29.21M | -70.05M | 868.06M | 0 |
Operating Income | -118.31M▲ 0% | -159.47M▼ 34.8% | -233.78M▼ 46.6% | -767.7M▼ 228.4% | -855.68M▼ 11.5% | -593.51M▲ 30.6% | -215.01M▲ 63.8% | -1.05B▼ 387.7% | -206.3M▲ 80.3% |
Operating Margin % | -44.48% | -35.09% | -26.68% | -51.48% | -48.42% | -28.48% | -8.6% | -38.01% | -6.35% |
Operating Income Growth % | 30% | -34.79% | -46.6% | -228.38% | -11.46% | 30.64% | 63.77% | -387.74% | 80.33% |
EBITDA | -102.75M | -136.39M | -183.53M | -604.33M | -675.33M | -395.95M | -8.4M | -833.84M | -206.3M |
EBITDA Margin % | -38.63% | -30.01% | -20.94% | -40.52% | -38.22% | -19% | -0.34% | -30.22% | -6.35% |
EBITDA Growth % | 34.76% | -32.73% | -34.57% | -229.27% | -11.75% | 41.37% | 97.88% | -9821.99% | 75.26% |
D&A (Non-Cash Add-back) | 15.55M | 23.08M | 50.25M | 163.36M | 180.35M | 197.56M | 206.61M | 214.86M | 0 |
EBIT | -114.38M | -140.54M | -397.71M | -817.24M | -829.63M | -618.66M | -177.32M | -1B | 0 |
Net Interest Income | -206K | -36.79M | -27.27M | -10.55M | -12.88M | -13.91M | -24.42M | -31.97M | 0 |
Interest Income | 0 | 0 | 23.77M | 6.57M | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 206K | 36.79M | 51.04M | 17.12M | 12.88M | 13.91M | 24.42M | 31.97M | -39.36M |
Other Income/Expense | 3.73M | -15.59M | -172.66M | -61.37M | 13.17M | -39.06M | 13.27M | 12.54M | -5.71M |
Pretax Income | -114.58M▲ 0% | -175.06M▼ 52.8% | -406.44M▼ 132.2% | -829.06M▼ 104.0% | -842.51M▼ 1.6% | -632.57M▲ 24.9% | -201.75M▲ 68.1% | -1.04B▼ 413.6% | -212.01M▲ 79.5% |
Pretax Margin % | -43.08% | -38.52% | -46.38% | -55.59% | -47.68% | -30.35% | -8.07% | -37.56% | -6.53% |
Income Tax | -187K | 92K | -193.35M | -5.46M | -246.88M | -9.06M | 2.4M | -7.3M | -4.06M |
Effective Tax Rate % | 0.16% | -0.05% | 47.57% | 0.66% | 29.3% | 1.43% | -1.19% | 0.7% | 1.92% |
Net Income | -114.4M▲ 0% | -175.15M▼ 53.1% | -213.09M▼ 21.7% | -823.61M▼ 286.5% | -595.63M▲ 27.7% | -623.51M▼ 4.7% | -204.15M▲ 67.3% | -1.03B▼ 404.0% | -207.95M▲ 79.8% |
Net Margin % | -43.01% | -38.54% | -24.32% | -55.22% | -33.71% | -29.91% | -8.17% | -37.29% | -6.4% |
Net Income Growth % | 31.59% | -53.11% | -21.66% | -286.51% | 27.68% | -4.68% | 67.26% | -403.97% | 79.79% |
Net Income (Continuing) | -114.4M | -175.15M | -213.09M | -823.61M | -595.63M | -623.51M | -204.15M | -1.03B | 0 |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.99▲ 0% | -1.43▼ 44.4% | -1.62▼ 13.3% | -5.45▼ 236.4% | -3.48▲ 36.1% | -3.54▼ 1.7% | -1.13▲ 68.1% | -5.59▼ 394.7% | -1.10▲ 80.3% |
EPS Growth % | 39.26% | -44.44% | -13.29% | -236.42% | 36.15% | -1.72% | 68.08% | -394.69% | 80.32% |
EPS (Basic) | -0.99 | -1.43 | -1.62 | -5.45 | -3.48 | -3.54 | -1.13 | -5.59 | -1.10 |
Diluted Shares Outstanding | 115.68M | 122.21M | 131.26M | 151.14M | 171.35M | 176.35M | 180.14M | 184.2M | 188.69M |
Basic Shares Outstanding | 115.68M | 122.21M | 131.26M | 151.14M | 171.35M | 176.35M | 180.14M | 184.2M | 188.69M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
EXAS Balance Sheet
Exact Sciences Corporation (EXAS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 487.22M | 1.23B | 553.94M | 2.2B | 1.43B | 982.26M | 1.19B | 1.57B | 1.56B |
Cash & Short-Term Investments | 424.71M | 1.12B | 323.65M | 1.84B | 1.03B | 632.06M | 777.64M | 1.04B | 964.71M |
Cash Only | 77.49M | 160.43M | 177.25M | 1.49B | 315.47M | 242.49M | 605.38M | 600.89M | 956M |
Short-Term Investments | 347.22M | 963.75M | 146.4M | 348.7M | 715M | 389.56M | 172.27M | 437.14M | 8.71M |
Accounts Receivable | 26.42M | 45.33M | 130.36M | 233.19M | 216.65M | 158.04M | 203.62M | 248.97M | 298.65M |
Days Sales Outstanding | 36.25 | 36.41 | 54.3 | 57.07 | 44.75 | 27.68 | 29.73 | 32.94 | 33.57 |
Inventory | 26.03M | 39.15M | 61.72M | 92.27M | 104.99M | 118.26M | 127.47M | 162.38M | 166.2M |
Days Inventory Outstanding | 119.95 | 121.11 | 103.96 | 95.05 | 83.54 | 65.27 | 63.08 | 70.54 | 61.63 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 73.9M | 85.63M | 122.05M | 126.28M |
Total Non-Current Assets | 111.34M | 295.95M | 2.95B | 2.73B | 5.26B | 5.24B | 5.28B | 4.36B | 4.3B |
Property, Plant & Equipment | 79.99M | 245.26M | 581.77M | 577.93M | 754.47M | 851.76M | 842.06M | 810.63M | 831M |
Fixed Asset Turnover | 3.33x | 1.85x | 1.51x | 2.58x | 2.34x | 2.45x | 2.97x | 3.40x | 3.91x |
Goodwill | 1.98M | 17.28M | 1.2B | 1.24B | 2.34B | 2.35B | 2.37B | 2.37B | 2.37B |
Intangible Assets | 22.23M | 29M | 1.14B | 847.12M | 2.09B | 1.96B | 1.89B | 1.01B | 919.92M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 7.15M | 4.42M | 23.32M | 63.77M | 74.59M | 90.58M | 177.39M | 169.72M | 185.81M |
Total Assets | 598.56M▲ 0% | 1.52B▲ 154.6% | 3.51B▲ 130.0% | 4.93B▲ 40.5% | 6.68B▲ 35.7% | 6.23B▼ 6.9% | 6.47B▲ 3.9% | 5.93B▼ 8.4% | 5.86B▼ 1.1% |
Asset Turnover | 0.44x | 0.30x | 0.25x | 0.30x | 0.26x | 0.33x | 0.39x | 0.47x | 0.55x |
Asset Growth % | 58.75% | 154.61% | 130.03% | 40.49% | 35.73% | -6.85% | 3.93% | -8.39% | -1.14% |
Total Current Liabilities | 68.12M | 136.59M | 236.49M | 633.1M | 517.07M | 412.75M | 514.7M | 732.19M | 641.15M |
Accounts Payable | 16.14M | 28.14M | 25.97M | 35.71M | 67.83M | 74.92M | 78.82M | 89.57M | 175.87M |
Days Payables Outstanding | 74.36 | 87.06 | 43.74 | 36.79 | 53.97 | 41.35 | 39 | 38.91 | 65.22 |
Short-Term Debt | 182K | 8K | 834K | 314.03M | 0 | 0 | 50M | 249.15M | 33.59M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 29.08M | 44.51M | 103.63M | 162.92M | 214.49M | 211.5M | 262.44M | 223.7M | 607.56M |
Current Ratio | 7.15x | 8.99x | 2.34x | 3.47x | 2.76x | 2.38x | 2.32x | 2.15x | 2.43x |
Quick Ratio | 6.77x | 8.70x | 2.08x | 3.33x | 2.56x | 2.09x | 2.07x | 1.92x | 2.17x |
Cash Conversion Cycle | 81.84 | 70.46 | 114.51 | 115.33 | 74.32 | 51.6 | 53.81 | 64.57 | 29.99 |
Total Non-Current Liabilities | 10.02M | 706.91M | 981.21M | 2.06B | 2.78B | 2.77B | 2.81B | 2.79B | 2.82B |
Long-Term Debt | 4.27M | 689.24M | 827.64M | 1.88B | 2.18B | 2.24B | 2.31B | 2.32B | 2.49B |
Capital Lease Obligations | 0 | 0 | 118.67M | 121.08M | 182.17M | 182.4M | 161.07M | 157.13M | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5.75M | 17.67M | 34.91M | 51.34M | 417.78M | 352.46M | 335.98M | 315.5M | 329.32M |
Total Liabilities | 78.14M | 843.08M | 1.22B | 2.69B | 3.3B | 3.18B | 3.33B | 3.53B | 3.46B |
Total Debt | 4.45M | 689.25M | 955.03M | 2.33B | 2.38B | 2.45B | 2.55B | 2.75B | 2.52B |
Net Debt | -73.04M | 528.82M | 777.77M | 839.33M | 2.07B | 2.2B | 1.95B | 2.15B | 1.57B |
Debt / Equity | 0.01x | 1.01x | 0.42x | 1.04x | 0.70x | 0.80x | 0.81x | 1.15x | 1.05x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | -574.32x | -4.33x | -4.58x | -44.84x | -66.44x | -42.68x | -8.80x | -32.80x | - |
Total Equity | 520.42M▲ 0% | 680.94M▲ 30.8% | 2.29B▲ 236.0% | 2.24B▼ 2.3% | 3.39B▲ 51.5% | 3.04B▼ 10.2% | 3.15B▲ 3.4% | 2.4B▼ 23.6% | 2.4B▼ 0.0% |
Equity Growth % | 55.21% | 30.84% | 236.01% | -2.29% | 51.53% | -10.17% | 3.36% | -23.62% | -0.05% |
Book Value per Share | 4.50 | 5.57 | 17.43 | 14.79 | 19.77 | 17.26 | 17.46 | 13.04 | 12.72 |
Total Shareholders' Equity | 520.42M | 680.94M | 2.29B | 2.24B | 3.39B | 3.04B | 3.15B | 2.4B | 2.4B |
Common Stock | 1.21M | 1.23M | 1.48M | 1.59M | 1.74M | 1.78M | 1.81M | 1.86M | 1.91M |
Retained Earnings | -860.61M | -1.04B | -1.12B | -2.05B | -2.64B | -3.27B | -3.47B | -4.5B | -4.71B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -750K | -1.42M | -100K | 526K | -1.44M | -5.24M | 1.43M | -944K | 2.36M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EXAS Cash Flow Statement
Exact Sciences Corporation (EXAS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -71.72M | -69.33M | -111.66M | 136.48M | -102.24M | -223.56M | 156.12M | 210.54M | 491.44M |
Operating CF Margin % | -26.96% | -15.25% | -12.74% | 9.15% | -5.79% | -10.73% | 6.25% | 7.63% | 15.14% |
Operating CF Growth % | 44.86% | 3.34% | -61.06% | 222.24% | -174.91% | -118.67% | 169.83% | 34.86% | 133.42% |
Net Income | -114.4M | -175.15M | -213.09M | -848.53M | -595.63M | -623.51M | -204.15M | -1.03B | -207.95M |
Depreciation & Amortization | 15.55M | 23.08M | 50.25M | 163.36M | 180.35M | 197.56M | 206.61M | 214.86M | 221.58M |
Stock-Based Compensation | 35.51M | 60.26M | 108.48M | 152.91M | 253.06M | 206.82M | 231.31M | 214.88M | 217.67M |
Deferred Taxes | -115K | -2.78M | -193.6M | -9.86M | -253.17M | -11.9M | -955K | -10.12M | -1.54M |
Other Non-Cash Items | -601K | 26.17M | 189.87M | 721.34M | 202.04M | 33.84M | -76.36M | 875.78M | 261.69M |
Working Capital Changes | -7.68M | -911K | -53.56M | -42.73M | 111.11M | -26.38M | -342K | -56.01M | 0 |
Change in Receivables | -17.53M | -17.29M | -27.63M | -100.53M | 25.15M | 61.09M | -43.42M | -46.26M | -48.89M |
Change in Inventory | -19.19M | -12.73M | -19.04M | -30.31M | -9.22M | -13.23M | -7.69M | -34.91M | -3.77M |
Change in Payables | 15.38M | 11.33M | 0 | 46.38M | 0 | 0 | 0 | 43.54M | 214.04M |
Cash from Investing | -160.81M | -781.91M | -124.43M | -702.04M | -1.08B | 74.07M | 49.68M | -442.15M | 195.12M |
Capital Expenditures | -69.24M | -150.67M | -172.65M | -64.35M | -135.77M | -214.46M | -124.19M | -135.99M | -134.66M |
CapEx % of Revenue | 26.03% | 33.15% | 19.7% | 4.31% | 7.68% | 10.29% | 4.97% | 4.93% | 4.15% |
Acquisitions | -5.98M | -17.91M | -973.86M | -22.61M | -517.77M | -14.69M | -52.41M | -45M | -75M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -109.34M | -614.3M | -1M | -411.8M | -58.82M | 24.45M | -250K | -225K | 28.27M |
Cash from Financing | 260.96M | 934.14M | 253.18M | 1.88B | 8.47M | 76.48M | 159.77M | 231.87M | -338.09M |
Debt Issued (Net) | -376K | 920.67M | 236.12M | 974.24M | -23.75M | 50M | 137.98M | 216.75M | 0 |
Equity Issued (Net) | 1000K | 0 | 0 | 1000K | 0 | 0 | 0 | 1000K | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 4.89M | 0 | 0 | 0 | 0 | 0 | 0 | 26.54M |
Other Financing | 7.94M | 13.48M | 17.06M | 43.68M | 32.22M | 26.48M | 21.79M | -17.75M | -338.09M |
Net Change in Cash | 28.57M▲ 0% | 82.94M▲ 190.3% | 17.1M▼ 79.4% | 1.31B▲ 7585.5% | -1.18B▼ 189.5% | -72.98M▲ 93.8% | 366.88M▲ 602.7% | -3.04M▼ 100.8% | 349.36M▲ 11595.9% |
Free Cash Flow | -140.96M▲ 0% | -220M▼ 56.1% | -284.31M▼ 29.2% | 72.13M▲ 125.4% | -238M▼ 430.0% | -438.02M▼ 84.0% | 31.93M▲ 107.3% | 74.55M▲ 133.5% | 356.78M▲ 378.6% |
FCF Margin % | -53% | -48.41% | -32.44% | 4.84% | -13.47% | -21.02% | 1.28% | 2.7% | 10.99% |
FCF Growth % | 2.73% | -56.07% | -29.23% | 125.37% | -429.96% | -84.04% | 107.29% | 133.48% | 378.6% |
FCF per Share | -1.22 | -1.80 | -2.17 | 0.48 | -1.39 | -2.48 | 0.18 | 0.40 | 1.89 |
FCF Conversion (FCF/Net Income) | 0.63x | 0.40x | 0.52x | -0.17x | 0.17x | 0.36x | -0.76x | -0.20x | -2.36x |
Interest Paid | 0 | 0 | 5.13M | 0 | 10.73M | 11.52M | 18.78M | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EXAS Key Ratios
Exact Sciences Corporation (EXAS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -50.51% | -26.74% | -29.16% | -14.35% | -36.41% | -21.18% | -19.39% | -6.6% | -37.09% | -8.66% |
Return on Invested Capital (ROIC) | -43.44% | -24.01% | -14.43% | -8.2% | -18.75% | -15.05% | -8.32% | -3.12% | -16.3% | -3.63% |
Gross Margin | 54.52% | 70.23% | 74.04% | 75.27% | 76.24% | 74.04% | 68.27% | 70.49% | 69.55% | 69.69% |
Net Margin | -168.26% | -43.01% | -38.54% | -24.32% | -55.22% | -33.71% | -29.91% | -8.17% | -37.29% | -6.4% |
Debt / Equity | 0.02x | 0.01x | 1.01x | 0.42x | 1.04x | 0.70x | 0.80x | 0.81x | 1.15x | 1.05x |
Interest Coverage | -793.50x | -574.32x | -4.33x | -4.58x | -44.84x | -66.44x | -42.68x | -8.80x | -32.80x | - |
FCF Conversion | 0.78x | 0.63x | 0.40x | 0.52x | -0.17x | 0.17x | 0.36x | -0.76x | -0.20x | -2.36x |
Revenue Growth | 151.99% | 167.66% | 70.86% | 92.82% | 70.19% | 18.49% | 17.95% | 19.93% | 10.37% | 17.69% |
Related:EXAS Dividend History·EXAS Revenue History·EXAS Price History·EXAS P/E History·EXAS Financial Ratios·EXAS Institutional Holders
EXAS SEC Filings & Documents
Exact Sciences Corporation (EXAS) SEC filings — annual & quarterly reports (10-K, 10-Q)
EXAS Frequently Asked Questions
Exact Sciences Corporation (EXAS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Exact Sciences Corporation (EXAS) reported $3.25B in revenue for fiscal year 2025.
Exact Sciences Corporation (EXAS) grew revenue by 17.7% over the past year. This is strong growth.
Exact Sciences Corporation (EXAS) reported a net loss of $207.9M for fiscal year 2025.
Dividend & Returns
Exact Sciences Corporation (EXAS) has a return on equity (ROE) of -8.7%. Negative ROE indicates the company is unprofitable.
Exact Sciences Corporation (EXAS) generated $356.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.